May 7, 2020
Rheumatoid arthritis patients on Medicare seeing increased out-of-pocket costs for specialty medications
After a sharp drop in out-of-pocket costs between 2010 and 2011, Medicare patients who use specialty biologic medications for rheumatoid arthritis have seen higher out-of-pocket spending for those same drugs because of gradual price increases, a new study finds.
By Jake Lowary